Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
*company not country
Pharma have known this is phase 1 and are interested. This has been stated many times.
The company has said they do not need to raise money and even if they did need more capital in the future, they have small assets they already own that could be sold to fund their pipeline.
Besides, once a deal for POLB 001 is made, they will have plenty of cash to develop the country further.
From Tuesday’s presentation
GSK acquires Affinivax
$2.1b upfront + $1.2b follow-on, May 2022
Pneumococcal vaccine & vaccine platform
Pfizer acquired ReViral
up to $525m, April 2022
Respiratory Syncytial Virus (RSV)
Bav Nordic licence Chinese
rights to Nuance Pharma
$12.5m upfront+ $200m follow-
on, Mar 2022. RSV
Bav Nordic acquires vaccines
from Emergent
$270m upfront + $110m
milestones, February 2023
There is a lot of variation there, and nobody should be predicting the value of this really. Jeremy calling this a “blockbuster” is very encouraging to me personally, but make of these numbers what you will.
Ya know that drug we were testing? Turns out it’s top banana! And it might help the side effects of cancer treatment. And it might be useful in other areas. Areas plural. No biggy.
This company goes from strength to strength. The drug passes the trial…delivering results ahead of Q2 schedule…strong potential for development of the molecule in other areas. This is a tightly run ship and I’m very happy to be heavily invested here. Well done to Jeremy and the team.
In the extra year they were waiting for FDA approval, didn’t they say they would be discussing sales with potential buyers? They weren’t just doing nothing. Purely speculation, but I believe in due course we will receive a monster RNS for either sales of product or sale of the company. If they are finalising such things, NDA(s) will likely be in place, explaining the lack of news.
When brokers set their targets, is there a standard time that is implied i.e. a year? I’ve never understood.
Scinv, have a day off, eh? Not a single person believes your diatribe.
https://www.**********.co.uk/articles/new-article-a67fd9d
on the markets of vox
When the price shot up to 11p in anticipation of POLB 001 results, there would quite likely have been a sell off, regardless of the news - just a buy on rumour, sell on news situation; especially with the markets as they are.
Now we have the positive initial results and the price has been steadily creeping up, I feel we have a good foundation for the share price, moving forwards. Looking forward to the presentation on Monday to get the reaction from the conference this week.
Current market cap of £40m. Deals with big pharma will already be discussed with these initial results, in anticipation of full results in Q2. Market cap will be multiples of this presuming a deal is made. And that’s just with POLB 001; yet alone the other projects. Current price is madness.
Holy moly! This is fantastic! Big pharma, with whom Poolbeg have been in close contact for months, must be rubbing their hands with glee! And opening their wallets wide! Well done Jeremy and team.
It was a double blind trial so, no, they wouldn’t know if it was efficacious at trial end.
“ The comprehensive dataset is expected to facilitate progression of the product to the next clinical phase for potential partners”.
This is the important bit.
A sell off because people were expecting a pharma deal to be announced with the completed study, perhaps; and full results not until Q2. We might get indicative results before then.
Scinv has clearly demonstrated he doesn’t understand what is going on here and is just trolling. Let’s give him/her a mince pie and see if it passifies him/her.
Exactly. The results of a trial like this can be on a spectrum, not necessarily binary. You said it yourself, they will design the next step, which is marketable to big pharma. I’m glad we agree this is going well.
Did you see the part where it said “The comprehensive dataset is expected to facilitate progression of the product to the next clinical phase for potential partners”. They wouldn’t say that if it had failed. Drug trials only go to the next clinical phase if they are successful. How can you spin that?
He said in the interview 300 units in 3 weeks in July, but they’ve doubled the workforce since then, so by your calculations 3200 units by year end.
Where was JW talking about this last night, please? I’d like to listen to that.
Justin changing his position is reasonable, it’s just a shame that it affects the SP as his followers often follow. This is now massively undervalued IMO and a great price to top up. Depends on your expected timeframe.